Studies on AIC.
Our latest studies and findings, from clinical case reports to conference presentations.
Sustained Deep Biochemical Response in Multiple Myeloma Managed with AIC Therapy: A Two-Year Case Report
A woman in her late 60s with IgG-lambda multiple myeloma reached deep remission on AIC alongside targeted therapy, with M-spike, IgG, and free light chains falling and kidney function and anemia recovering. By April 2026 all targeted drugs were discontinued, with disease stable on AIC alone.
Conference · AACR 2025Reflections from AACR 2025
A firsthand account from the American Association for Cancer Research meeting in Chicago, where researchers from the University of Arkansas took interest in AIC against multiple myeloma.
Clinical study · Bone densityAIC and Bone Mineral Density: Moffitt Cancer Center
A collaboration with Moffitt Cancer Center and CBHI across 135 subjects found mean bone mineral density rose 9.4%, with significant gains (p=0.0001) in osteopenia and osteoporosis across age and BMI groups.
Preclinical · OsteoporosisAIC as a Therapeutic Agent for Osteoporosis
In ovariectomy-induced mouse models over 13 weeks, AIC improved bone density and microstructure and suppressed osteoclast genes (TRAP, NFATc1), with no adverse effects on organ health. Sungkyunkwan University.
Clinical study · Bone densityAIC Enhances Bone Mineral Density in an Asian Population
Across 82 participants taking daily AIC for about eight months, T-scores and BMD improved significantly (p<0.0001); 65% of osteopenic individuals returned to normal density and 12% of osteoporotic patients reached normal, with a favorable safety profile.
